Revenue Performance - Total revenue for the three months ended September 30, 2025, was $28.1 million, representing a 31% increase compared to $21.4 million for the same period in 2024[190]. - Product revenue for the three months ended September 30, 2025, was $26.3 million, an increase of $6.3 million, or 32%, compared to the same period in 2024[191]. - Cell processing product revenue increased by $6.3 million, or 33%, during the three months ended September 30, 2025, driven by increased customer demand for commercially approved therapies[192]. - Rental revenue for the three months ended September 30, 2025, was $1.8 million, representing a 24% increase compared to $1.4 million for the same period in 2024[197]. - Total revenue for the nine months ended September 30, 2025, was $77.4 million, a 30% increase from $59.5 million for the same period in 2024[190]. - Product revenue from cell processing products increased by $16.6 million, or 31%, during the nine months ended September 30, 2025, compared to the same period in 2024[193]. - Product revenue from evo and Thaw products increased by $0.9 million, or 54%, during the nine months ended September 30, 2025, compared to the same period in 2024[195]. - Service revenues were immaterial during the three and nine months ended September 30, 2025, and 2024[196]. Operating Expenses - Total operating expenses increased by $6.3 million, or 29%, for the three months ended September 30, 2025, and by $30.8 million, or 48%, for the nine months ended September 30, 2025 compared to the same periods in 2024[199]. - Cost of product, rental, and service revenue rose by $2.7 million, or 37%, for the three months ended September 30, 2025, and by $7.2 million, or 36%, for the nine months ended September 30, 2025 compared to the same periods in 2024[200]. - General and administrative expenses increased by $2.7 million, or 29%, for the three months ended September 30, 2025, and by $5.9 million, or 20%, for the nine months ended September 30, 2025 compared to the same periods in 2024[204][205]. - Research and development expenses increased by $0.8 million, or 43%, for the three months ended September 30, 2025, and by $1.6 million, or 27%, for the nine months ended September 30, 2025 compared to the same periods in 2024[209][210]. Financial Position - The company had $98.4 million in cash, cash equivalents, and available-for-sale securities as of September 30, 2025, down from $109.2 million at the end of 2024[216]. - The company believes its current level of cash and liquid assets will be sufficient to meet liquidity needs for at least the next twelve months[223]. - Net cash provided by operating activities increased to $15.2 million for the nine months ended September 30, 2025, up from $6.8 million in the same period of 2024, reflecting stronger revenues and improved working capital management[225]. - Net cash used in investing activities rose to $72.7 million for the nine months ended September 30, 2025, compared to $15.3 million in 2024, primarily due to $61.4 million in additional purchases of marketable securities[226]. - The company invested $10.2 million in the acquisition of PanTHERA during the nine months ended September 30, 2025, which was $2.8 million less than the cash used for the divestiture of Global Cooling in Q2 2024[227]. - Net cash used in financing activities totaled $8.4 million for the nine months ended September 30, 2025, compared to $2.7 million in 2024, driven by a $7.5 million increase in Term Loan payments[228]. - As of September 30, 2025, the company's total short-term purchase obligations amounted to $7.4 million[230]. - The company does not use derivative financial instruments in its investment portfolio, and fluctuations in interest rates have not materially impacted its consolidated financial statements[234]. Strategic Actions - The divestiture of SAVSU was completed on October 6, 2025, and is presented as part of continuing operations as of September 30, 2025[181]. - The company continues to evaluate opportunities for organic growth innovations, partnerships, and acquisitions to maximize the value of its product platforms[180]. - The company entered into the SAVSU Purchase Agreement for an aggregate purchase price of $25.5 million on October 6, 2025[217]. - The PanTHERA Transaction was completed on April 4, 2025, with an aggregate purchase price of $16.8 million, including $11.5 million in cash[218]. - The company received net proceeds of $71.3 million from the SciSafe Divestiture on November 12, 2024[221]. Interest Income - Interest income increased by $0.7 million, or 321%, for the three months ended September 30, 2025, and by $2.6 million, or 369%, for the nine months ended September 30, 2025 compared to the same periods in 2024[213][215].

Revenue and Growth - Cell Processing revenue for Q3 2025 was $25.4 million, up 33% from Q3 2024[1] - Total revenue for Q3 2025 was $28.1 million, an increase of 31% from $21.4 million in Q3 2024[12] - The company raised its 2025 full-year Cell Processing revenue guidance to $93.0 million - $94.0 million, reflecting year-over-year growth of 26% to 28%[25] - The company expects total 2025 revenue guidance of $95.0 million to $96.0 million, representing a 27% - 29% increase compared to 2024[21] - Product revenue for Q3 2025 was $26,250,000, a 31.6% increase from $19,928,000 in Q3 2024[37] - Total revenue for the nine months ended September 30, 2025, reached $77,429,000, up 30% from $59,539,000 in the same period of 2024[42] - Total revenues for the nine months ended September 30, 2025, reached $71,449,000, compared to $64,000,000 for the same period in 2024, reflecting a growth of approximately 11%[53] Profitability and Margins - Adjusted EBITDA for Q3 2025 was $7.8 million, or 28% of revenue, compared to $5.0 million, or 23% of revenue, in Q3 2024[24] - Gross margin (GAAP) for Q3 2025 was 62%, down from 63% in Q3 2024, while adjusted gross margin was 64%, down from 67%[18] - Gross profit for Q3 2025 was $17,325,000, representing a gross margin of 62%, compared to 63% in Q3 2024[42] - Adjusted operating income for Q3 2025 was $1,293,000, compared to $167,000 in Q3 2024[46] - Adjusted EBITDA for the three months ended September 30, 2025, was $7,832,000, representing 28% of revenue, compared to $5,021,000 or 23% of revenue in the same quarter of 2024[50] - Adjusted gross margin for the three months ended September 30, 2025, was 66%, compared to 67% in the same period of 2024[56] Net Income and Losses - Net income (GAAP) for Q3 2025 was $0.6 million, compared to a net loss of $0.5 million in Q3 2024[18] - Net income for Q3 2025 was $621,000, a significant improvement from a net loss of $1,703,000 in Q3 2024[38] - For the three months ended September 30, 2025, BioLife Solutions reported a net income of $621,000 compared to a net loss of $471,000 for the same period in 2024[47] - Adjusted net income for the three months ended September 30, 2025, was $2,044,000, significantly up from $34,000 in the prior year[47] - Operating loss for the nine months ended September 30, 2025, was $17,949,000, compared to a loss of $5,019,000 in the same period of 2024[46] - Operating loss for the nine months ended September 30, 2025, was $(16,917,000), compared to $(4,481,000) for the same period in 2024[53] Cash and Assets - Cash, cash equivalents, and marketable securities as of September 30, 2025, were $98.4 million[24] - Cash and cash equivalents at the end of Q3 2025 were $29,481,000, down from $24,161,000 at the end of Q3 2024[41] - Total assets as of September 30, 2025, were $392,081,000, slightly down from $399,487,000 at the end of 2024[40] - The company reported a net cash provided by operating activities of $15,199,000 for the nine months ended September 30, 2025, compared to $6,786,000 in 2024[41] Expenses and Costs - The company incurred $15,521,000 in IPR&D expenses during the nine months ended September 30, 2025, primarily related to the PanTHERA acquisition[50] - The company reported a significant increase in share-based compensation, totaling $15,897,000 for the nine months ended September 30, 2025, compared to $12,233,000 in the prior year[50] - The company incurred acquisition and divestiture costs of $1,245,000 for FY2024, with YTD 2025 costs amounting to $1,309,000[60][61] - Depreciation expenses for FY2024 totaled $643,000, while YTD 2025 expenses reached $588,000[60][61] - Interest expense for FY2024 was $766,000, with interest income for YTD 2025 reported at $(1,875,000)[60][61] Divestitures and Acquisitions - The divestiture of the evo cold chain logistics business was completed for $25.5 million in cash[7] - The company anticipates the divestiture of evo to qualify as Discontinued Operations in the Annual Report for the year ended December 31, 2025[51] Accumulated Deficit - The accumulated deficit increased to $(350,766,000) as of September 30, 2025, from $(335,101,000) at the end of 2024[40] Other Financial Metrics - For FY2024, the company reported a total loss from continuing operations of $8,789,000, with Q3 showing a slight income of $300,000[60] - Adjusted EBITDA from continuing operations for FY2024 was $13,337,000, representing 18% of revenue[60] - In Q1 2025, the company experienced a loss from continuing operations of $14,634,000, with Q2 showing a significant loss of $15,454,000[61] - Adjusted EBITDA from continuing operations for YTD 2025 reached $17,722,000, which is 25% of revenue[61] - Share-based compensation (non-cash) totaled $15,282,000 for FY2024, with Q1 2025 reporting $15,468,000[60][61] - The company recorded an inventory reserve cost of $247,000 in Q4 2024[60]

Core Insights - BioLife Solutions, Inc. will release its third quarter 2025 financial results on November 6, 2025, after market close [1] - A conference call and live webcast will be held on the same day at 4:30 PM ET to discuss the financial results and provide a business update [1] Company Overview - BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market [3] - The company specializes in solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution [3]

Core Insights - BioLife Solutions, Inc. has announced the sale of its wholly owned cold chain logistics subsidiary, SAVSU Cleo Technologies, LLC, for $25.5 million in cash to Peli BioThermal, enhancing its focus on high-margin recurring revenue [1][2]. Company Overview - BioLife Solutions is a leading developer and supplier of cell processing tools and services for the cell and gene therapy market, facilitating the commercialization of new therapies by providing solutions that maintain the health and function of biologic materials during various stages [2].

Group 1 - The article emphasizes the importance of focusing on companies with a defensible competitive advantage and business models that can generate significant operational leverage [1] - BioLife (NASDAQ: BLFS) is highlighted for returning to its core focus on bio preservation media, which constitutes 85% of its cell processing segment [2] - The SHU Growth Portfolio service offers a buy and hold strategy for small companies with high growth potential, providing buy alerts and market updates [3] Group 2 - The analyst has a beneficial long position in BioLife shares, indicating confidence in the company's prospects [4] - The article does not provide specific investment recommendations or guarantees regarding future performance [5]

Core Viewpoint - BioLife Solutions, Inc. (BLFS) has received an upgrade to a Zacks Rank 1 (Strong Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling pressure that affects stock prices [4]. Company Performance Indicators - BioLife Solutions is expected to earn $0.05 per share for the fiscal year ending December 2025, with no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for BioLife Solutions has increased by 150%, reflecting a significant positive revision in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of BioLife Solutions to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [10].

Group 1 - BioLife Solutions, Inc. (BLFS) shares have increased by 1.6% over the past four weeks, closing at $22.37, with a mean price target of $31.3 indicating a potential upside of 39.9% [1] - The average of 10 short-term price targets ranges from $30.00 to $34.00, with a standard deviation of $1.42, suggesting a potential increase of 34.1% to 52% from the current price level [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases, as indicated by a 150% increase in the Zacks Consensus Estimate for the current year [11][12] Group 2 - BLFS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While consensus price targets may not be reliable for predicting exact price movements, they can provide a directional guide for potential stock performance [14]

Financial Performance - BioLife Solutions, Inc. (BLFS) reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.02, and improved from a loss of $0.06 per share a year ago, representing an earnings surprise of +100.00% [1] - The company posted revenues of $25.42 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 6.98%, although this is a decline from year-ago revenues of $28.33 million [2] - Over the last four quarters, BioLife Solutions has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance and Outlook - BioLife Solutions shares have declined approximately 18.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $24.55 million, and for the current fiscal year, it is $0.02 on revenues of $97.83 million [7] Industry Context - The Medical - Products industry, to which BioLife Solutions belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5]

Financial Data and Key Metrics Changes - In Q2 2025, total revenue increased by 29% year over year to $25.4 million, driven by a 28% increase in cell processing revenue [16][6] - Adjusted EBITDA margin expanded by 400 basis points to 24%, reflecting strong operating leverage [6] - GAAP net loss was $15.8 million or $0.33 per share, compared to a net loss of $5.6 million or $0.12 per share in the prior year [20][16] Business Line Data and Key Metrics Changes - Cell processing revenue reached $23 million, marking a 28% year-over-year increase and a 6% sequential increase [8] - Biopreservation media (BPM) products accounted for approximately 85% of Q2 cell processing revenue, with top 20 customers contributing about 80% of BPM revenue [8][9] - Adjusted operating expenses totaled $16.9 million, up from $14 million in the prior year, largely due to increased stock-based compensation and IPR&D expenses related to the Panthera acquisition [19][16] Market Data and Key Metrics Changes - At the end of Q2, BPM products were embedded in 16 approved therapies and used in over 250 relevant commercially sponsored CGT trials in the U.S., representing over a 70% market share [10] - The company maintains a strong position in late-stage clinical development, with nearly 80% market share in Phase 3 clinical trials [10] Company Strategy and Development Direction - The company is focused on operational execution and disciplined capital allocation, with a sharpened focus on its product portfolio and market share in cell processing [7] - A strategic investment in Pluristics was made to explore product portfolio expansion into relevant adjacencies [12] - The company raised its full-year revenue guidance to $100 million to $103 million, reflecting a growth of 22% to 25% [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macro uncertainties, citing strong visibility from major customers [26] - The FDA's recent decision to remove the REMS requirement is viewed as a positive development for the CGT landscape, potentially enhancing patient access to therapies [13] - The company expects continued strength in cell processing revenue despite broader market uncertainties [7] Other Important Information - The company reported cash and marketable securities of $100.2 million at the end of Q2 2025 [21] - The acquisition of Panthera is expected to enhance market leadership in biopreservation and introduce new product lines [54] Q&A Session Summary Question: Guidance visibility and commercial ramps - Management indicated good visibility into revenue from top customers and expressed confidence in the second half of the year despite potential lumpiness between Q3 and Q4 [26][27] Question: Cross-selling dynamics - Management noted early traction in cross-selling efforts, with larger accounts showing interest in additional products [31] Question: CryoCase timeline - Management is in discussions with a large customer regarding changes to the CryoCase and has over 30 customers evaluating it [35] Question: Pluristics investment and competition - Management does not view Pluristics as a competitive threat but is interested in their assay development capabilities [40] Question: Panthera updates - The company remains on track to have commercial products from Panthera in the market by the second half of next year [42] Question: Demand trends in early clinical stages - Management noted a slight softness in demand from smaller Phase I and II customers but expects overall growth to continue [49] Question: Distribution channel visibility - Management has not seen any weakness in the distribution channel and remains confident in its strength for the remainder of the year [53] Question: M&A strategy - The company emphasizes a disciplined approach to M&A, focusing on strategic rationale and market leadership [60]

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) The financial information for the period ended June 30, 2025, reflects strategic divestitures and an acquisition, impacting revenue, net loss, and cash balances [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) The unaudited condensed consolidated financial statements for the period ended June 30, 2025, reflect significant changes due to strategic divestitures and an acquisition, with revenue growth but a net loss from continuing operations [Unaudited Condensed Consolidated Balance Sheets](index=4&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) Condensed consolidated balance sheet highlights show a decrease in cash and an increase in available-for-sale securities Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $31,902 | $95,386 | | Available-for-sale securities (Total) | $68,335 | $13,826 | | Total current assets | $125,432 | $148,761 | | Goodwill | $212,304 | $212,304 | | Total assets | $387,240 | $399,487 | | **Liabilities & Equity** | | | | Total current liabilities | $28,312 | $32,734 | | Debt, long-term | $0 | $4,997 | | Total liabilities | $40,085 | $50,578 | | Total shareholders' equity | $347,155 | $348,909 | - Cash and cash equivalents significantly decreased from **$95.4 million** at the end of 2024 to **$31.9 million** as of June 30, 2025, while available-for-sale securities increased substantially from **$13.8 million** to **$68.3 million**[9](index=9&type=chunk) [Unaudited Condensed Consolidated Statements of Operations](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) The statements of operations show increased revenue but a significant operating loss due to a one-time IPR&D expense Statement of Operations Summary (in thousands, except per share data) | Metric | Q2 2025 | Q2 2024 | Six Months 2025 | Six Months 2024 | | :--- | :--- | :--- | :--- | :--- | | Total revenue | $25,421 | $19,715 | $49,362 | $38,148 | | Total operating expenses | $42,064 | $21,021 | $67,222 | $42,749 | | IPR&D expense | $15,521 | $0 | $15,521 | $0 | | Operating loss | $(16,643) | $(1,306) | $(17,860) | $(4,601) | | Net loss from continuing operations | $(15,838) | $(5,560) | $(16,286) | $(8,759) | | Loss from discontinued operations | $0 | $(15,159) | $0 | $(22,181) | | Net loss | $(15,838) | $(20,719) | $(16,286) | $(30,940) | | Loss per share (continuing ops) | $(0.33) | $(0.12) | $(0.34) | $(0.19) | - A significant IPR&D expense of **$15.5 million** was recorded in Q2 2025, leading to a substantial increase in operating loss to **$16.6 million** for the quarter, compared to a **$1.3 million** loss in Q2 2024[12](index=12&type=chunk) [Unaudited Condensed Consolidated Statements of Cash Flows](index=12&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash flow statements indicate a net decrease in cash and cash equivalents, primarily driven by investing activities related to acquisitions and securities Cash Flow Summary for the Six Months Ended June 30 (in thousands) | Cash Flow Category | 2025 | 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $9,095 | $1,984 | | Net cash used in investing activities | $(66,709) | $(13,656) | | Net cash used in financing activities | $(5,870) | $(1,656) | | **Net decrease in cash and cash equivalents** | **$(63,484)** | **$(13,328)** | - Investing activities used **$66.7 million** in the first six months of 2025, primarily due to purchases of available-for-sale securities (**$64.3 million**) and an investment in IPR&D (**$10.2 million**) related to the PanTHERA acquisition[30](index=30&type=chunk) - Financing activities used **$5.9 million**, mainly due to **$5.0 million** in payments on term loans[30](index=30&type=chunk) [Notes to Unaudited Condensed Consolidated Financial Statements](index=15&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) The notes detail significant strategic changes, including the PanTHERA acquisition and divestitures of Global Cooling, SciSafe, and CBS - The company has undergone significant strategic changes, including the acquisition of PanTHERA CryoSolutions Inc. on April 4, 2025, and the divestiture of Global Cooling, SciSafe, and CBS, which are now treated as discontinued operations[35](index=35&type=chunk)[36](index=36&type=chunk)[37](index=37&type=chunk)[38](index=38&type=chunk) - The PanTHERA transaction was accounted for as an asset acquisition, with the **$15.5 million** value of its IPR&D technology being expensed immediately as it had no alternative future use[60](index=60&type=chunk)[61](index=61&type=chunk) - The company recorded a net loss on disposal of Global Cooling of **$8.9 million** and CBS of **$3.4 million**, and a net gain on disposal of SciSafe of **$28.1 million**[70](index=70&type=chunk)[77](index=77&type=chunk)[86](index=86&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=45&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes revenue growth to increased customer demand and discusses the impact of the PanTHERA acquisition on expenses, while affirming sufficient liquidity Revenue by Category - Six Months Ended June 30 (in thousands) | Revenue Category | 2025 | 2024 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | **Product revenue** | | | | | | Cell processing | $44,473 | $34,124 | $10,349 | 30% | | evo and Thaw | $1,535 | $731 | $804 | 110% | | **Rental revenue** | | | | | | evo and Thaw | $3,258 | $3,194 | $64 | 2% | | **Total revenue** | **$49,362** | **$38,148** | **$11,214** | **29%** | - The increase in cell processing product revenue was driven by an overall market improvement and increased demand from largest customers after a period of safety stock reduction in the prior year[183](index=183&type=chunk) - Total operating expenses for the six months ended June 30, 2025, increased by **57%** to **$67.2 million**, primarily due to the **$15.5 million** IPR&D expense related to the PanTHERA acquisition[187](index=187&type=chunk)[196](index=196&type=chunk) - The company believes its current cash, cash equivalents, and other liquid assets of **$100.2 million** are sufficient to meet liquidity needs for at least the next twelve months[201](index=201&type=chunk)[206](index=206&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=51&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company's primary market risk is interest rate exposure on investments and debt, managed through high-quality, short-term debt instruments, with no material impact reported - The company's main market risk is interest rate risk related to its marketable securities and long-term debt[213](index=213&type=chunk) - Risk is mitigated by investing in high-quality, short-term debt instruments and having long-term debt that is primarily at a fixed rate with a variable component subject to a ceiling[214](index=214&type=chunk)[215](index=215&type=chunk) - Management asserts that interest rate fluctuations have not materially impacted the financial statements[216](index=216&type=chunk) [Item 4. Controls and Procedures](index=52&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls were effective as of June 30, 2025, having remediated a prior material weakness and implemented new controls for the PanTHERA acquisition - Management concluded that disclosure controls and procedures were effective as of June 30, 2025[217](index=217&type=chunk) - A material weakness in internal control over financial reporting related to stock-based awards, identified as of December 31, 2024, was remediated during the quarter ended March 31, 2025[218](index=218&type=chunk) - New internal controls were implemented related to the acquisition of PanTHERA[219](index=219&type=chunk) [PART II. OTHER INFORMATION](index=53&type=section&id=PART%20II.%20OTHER%20INFORMATION) This section covers other required disclosures, including legal proceedings, risk factors, equity sales, defaults, mine safety, and exhibits [Item 1. Legal Proceedings](index=53&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently aware of any legal proceedings or claims expected to have a material adverse effect on its business or financial condition - The company reports no material legal proceedings[221](index=221&type=chunk) [Item 1A. Risk Factors](index=53&type=section&id=Item%201A.%20Risk%20Factors) There have been no material changes to the risk factors previously disclosed in the company's Annual Report on Form 10-K - No material changes to risk factors have occurred since the last Annual Report[222](index=222&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=53&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities or use of proceeds during the period - None reported[223](index=223&type=chunk) [Item 3. Defaults Upon Senior Securities](index=53&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities - None reported[224](index=224&type=chunk) [Item 4. Mine Safety Disclosures](index=53&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - None reported[225](index=225&type=chunk) [Item 5. Other Information](index=53&type=section&id=Item%205.%20Other%20Information) The company reported no other information required to be disclosed under this item - None reported[226](index=226&type=chunk) [Item 6. Exhibits](index=54&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including CEO and CFO certifications and XBRL interactive data files - The report includes standard CEO/CFO certifications and XBRL data files as exhibits[227](index=227&type=chunk)